ELUSYS

Elusys Therapeutics is dedicated to delivering innovative medical countermeasures that enable fast, effective, and durable protection against infectious agents. Our goal is to accelerate the development and commercialization of novel biodefense solutions, such as our anthrax antitoxin ANTHIM® (obiltoxaximab), for strategic government partners... Elusys Therapeutics leverages immune-stimulatory and immune-derived therapies to combat infectious disease. Our anthrax antitoxin obiltoxaximab, licensed as ANTHIM® in the United States and Canada and as NYXTHRACIS® in the Great Britain and the European Union, is a medical countermeasure to mitigate the effect of anthrax exposure after a natural incident or intentional attack. Our mission is to accelerate the development and commercialization of novel biodefense solutions to defend tomorrow today.

Also known as: Elusys Therapeutics, Elusys Therapeutics Inc.